Home » Stocks » EWTX

Edgewise Therapeutics, Inc. (EWTX)

Stock Price: $26.98 USD 0.15 (0.56%)
Updated Jun 17, 2021 12:47 PM EDT - Market open
Market Cap 1.25B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 1.56M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 17
Last Price $26.98
Previous Close $26.83
Change ($) 0.15
Change (%) 0.56%
Day's Open 26.99
Day's Range 26.98 - 28.34
Day's Volume 154,836
52-Week Range 21.07 - 40.49

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Is investor enthusiasm for new biotechnology companies waning? Based on the performance of the 35 biotechs that went public in the first quarter, that may be the case.

Other stocks mentioned: DBTX, RXRX, TAK
2 weeks ago - GuruFocus

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

2 weeks ago - Business Wire

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

1 month ago - Business Wire

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

1 month ago - Business Wire

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

1 month ago - Business Wire

They're both innovating in attractive areas where there's no competition on the radar.

Other stocks mentioned: HGEN
1 month ago - The Motley Fool

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

2 months ago - Business Wire

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, announced today the ...

2 months ago - Business Wire

Edgewise Therapeutics, a Phase 1 biotech developing small molecule therapies for rare muscle disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

3 months ago - NASDAQ

Edgewise Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

About EWTX

Edgewise Therapeutics' vision is to improve the lives of patients and families suffering from rare muscle disorders by building the world’s leading muscle-focused, precision medicine company. In less than four years, we have matured into a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by our holistic drug discovery approach to targeting the muscle as an organ, we have combi... [Read more...]

Industry
Biotechnology
IPO Date
Mar 26, 2021
CEO
Kevin Koch, Ph.D.
Employees
22
Stock Exchange
NASDAQ
Ticker Symbol
EWTX
Full Company Profile

Financial Performance

Financial Statements